Olympus Selected To Exhibit iTind Device For BPH Treatment At Vizient Innovative Technology Exchange

Olympus has been selected to exhibit the iTind device, a temporarily implanted device for relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange virtually September 21-23.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

Treatment with the iTind device avoids complications associated with drugs, surgery, or permanent implants, and it allows men to go back to their normal lives shortly after the treatment.i The iTind device works by reshaping the prostate — the device’s three nitinol (nickel titanium alloy) struts gradually expand during the 5-7 days the temporary implant is in place, creating channels through which urine can flow. A U.S. multicenter study showed that the iTind provides rapid and effective relief of BPH (benign prostatic hyperplasia) symptoms while preserving sexual function.ii Placement and retrieval can be done in a hospital, ambulatory surgery center, or medical office setting.

“Olympus is thrilled to bring the iTind device to the Vizient Innovative Technology Exchange,” said Randy Clark, President of the Olympus Medical Systems Group. “This truly minimally invasive treatment gives urologists and patients a further treatment option, one that rapidly relieves enlarged prostate symptoms while preserving sexual function. We are very excited to show off the iTind device and its positive outcomes as they align with our purpose of making people’s lives healthier, safer and more fulfilling.”

“Suppliers come to the Exchange hoping to be awarded an Innovative Technology contract, which signals health care providers of their product’s unique qualities,” said Debbie Archer, Procurement Compliance Director for Vizient. “We are pleased to include this technology in the group selected to participate.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has received over 2,800 technology submissions as part of its Innovative Technology Program.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.
The rehabilitation robotic glove is a training device that combines EMG electromyographic feedback and flexible robotics for patients with stroke or hand disabilities to train and repair dexterity.
Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices. The prospective, multicenter, randomized controlled study will enroll approximately 1,600 patients.
“This should be welcome news for patient care teams because a greater prediction rate with fewer false alerts translates into more effective and efficient care,” said Corey Centen, founder, president, and chief technical officer at Bodyport. “What’s more, use of the Cardiac Scale and the Congestion Index is a seamless transition for clinicians and patients because it enhances, rather than replaces, the existing pathways built around weight monitoring. The lower alert rate should lead to workflow efficiencies because care teams—who are often feeling overly burdened by the large number of notifications and data flowing in—will spend less time responding to false alerts.”
The potential of BC 007 extends beyond treating a single disease, making it a so-called platform technology. By neutralizing fAABs, BC 007 could potentially act against many fAAB-associated diseases.

By using this website you agree to accept Medical Device News Magazine Privacy Policy